Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

K Lyashchenko

Showing results (31-40 of 75) with videos related to

Pageof 8
Sort By:
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|November 20, 2025
Radiolabeling of CHX-A″-DTPA-Antibody Conjugates with [<sup>89</sup>Zr]ZrCl<sub>4</sub>Serge K Lyashchenko, Tullio V Esposito, Tuan Tran, et al.
Nature Communications|February 5, 2016
ALS-associated mutant FUS induces selective motor neuron degeneration through toxic gain of functionAarti Sharma, Alexander K Lyashchenko, Lei Lu, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|November 18, 2017
First-in-Human Human Epidermal Growth Factor Receptor 2-Targeted Imaging Using <sup>89</sup>Zr-Pertuzumab PET/CT: Dosimetry and Clinical Application in Patients with Breast CancerGary A Ulaner, Serge K Lyashchenko, Christopher Riedl, et al.
European Journal of Nuclear Medicine and Molecular Imaging|May 8, 2020
Comparison of <sup>68</sup>Ga-DOTA-JR11 PET/CT with dosimetric <sup>177</sup>Lu-satoreotide tetraxetan (<sup>177</sup>Lu-DOTA-JR11) SPECT/CT in patients with metastatic neuroendocrine tumors undergoing peptide receptor radionuclide therapySimone Krebs, Joseph A O'Donoghue, Evan Biegel, et al.
Nuclear Medicine and Biology|May 26, 2019
A rapid bead-based radioligand binding assay for the determination of target-binding fraction and quality control of radiopharmaceuticalsSai Kiran Sharma, Serge K Lyashchenko, Hijin A Park, et al.
Infection and Immunity|August 14, 2001
Characterization of the secreted MPT53 antigen of Mycobacterium tuberculosisS Johnson, P Brusasca, K Lyashchenko, et al.
EJNMMI Research|March 7, 2018
I-124 codrituzumab imaging and biodistribution in patients with hepatocellular carcinomaJorge A Carrasquillo, Joseph A O'Donoghue, Volkan Beylergil, et al.
Radiology|April 8, 2020
CD38-targeted Immuno-PET of Multiple Myeloma: From Xenograft Models to First-in-Human ImagingGary A Ulaner, Nicholas B Sobol, Joseph A O'Donoghue, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 24, 2019
Phase I Trial of Well-Differentiated Neuroendocrine Tumors (NETs) with Radiolabeled Somatostatin Antagonist <sup>177</sup>Lu-Satoreotide TetraxetanDiane Reidy-Lagunes, Neeta Pandit-Taskar, Joseph A O'Donoghue, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|May 9, 2025
Detection of HER2-Low Lesions Using HER2-Targeted PET Imaging in Patients with Metastatic Breast Cancer: A Paired HER2 PET and Tumor Biopsy AnalysisRandy Yeh, Fresia Pareja, Parnian Shobeiri, et al.
Pageof 8

Showing results (31-40 of 75) with videos related to

Sort By:
Pageof 8
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|November 20, 2025
Radiolabeling of CHX-A″-DTPA-Antibody Conjugates with [<sup>89</sup>Zr]ZrCl<sub>4</sub>Serge K Lyashchenko, Tullio V Esposito, Tuan Tran, et al.
Nature Communications|February 5, 2016
ALS-associated mutant FUS induces selective motor neuron degeneration through toxic gain of functionAarti Sharma, Alexander K Lyashchenko, Lei Lu, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|November 18, 2017
First-in-Human Human Epidermal Growth Factor Receptor 2-Targeted Imaging Using <sup>89</sup>Zr-Pertuzumab PET/CT: Dosimetry and Clinical Application in Patients with Breast CancerGary A Ulaner, Serge K Lyashchenko, Christopher Riedl, et al.
European Journal of Nuclear Medicine and Molecular Imaging|May 8, 2020
Comparison of <sup>68</sup>Ga-DOTA-JR11 PET/CT with dosimetric <sup>177</sup>Lu-satoreotide tetraxetan (<sup>177</sup>Lu-DOTA-JR11) SPECT/CT in patients with metastatic neuroendocrine tumors undergoing peptide receptor radionuclide therapySimone Krebs, Joseph A O'Donoghue, Evan Biegel, et al.
Nuclear Medicine and Biology|May 26, 2019
A rapid bead-based radioligand binding assay for the determination of target-binding fraction and quality control of radiopharmaceuticalsSai Kiran Sharma, Serge K Lyashchenko, Hijin A Park, et al.
Infection and Immunity|August 14, 2001
Characterization of the secreted MPT53 antigen of Mycobacterium tuberculosisS Johnson, P Brusasca, K Lyashchenko, et al.
EJNMMI Research|March 7, 2018
I-124 codrituzumab imaging and biodistribution in patients with hepatocellular carcinomaJorge A Carrasquillo, Joseph A O'Donoghue, Volkan Beylergil, et al.
Radiology|April 8, 2020
CD38-targeted Immuno-PET of Multiple Myeloma: From Xenograft Models to First-in-Human ImagingGary A Ulaner, Nicholas B Sobol, Joseph A O'Donoghue, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 24, 2019
Phase I Trial of Well-Differentiated Neuroendocrine Tumors (NETs) with Radiolabeled Somatostatin Antagonist <sup>177</sup>Lu-Satoreotide TetraxetanDiane Reidy-Lagunes, Neeta Pandit-Taskar, Joseph A O'Donoghue, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|May 9, 2025
Detection of HER2-Low Lesions Using HER2-Targeted PET Imaging in Patients with Metastatic Breast Cancer: A Paired HER2 PET and Tumor Biopsy AnalysisRandy Yeh, Fresia Pareja, Parnian Shobeiri, et al.
Pageof 8